Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival

Pharmacogenetics and Genomics

Volumn 17, Issue 5, 2007, Pages 331-338

  Long, Ji Rong ^a   Cai, Qiuyin ^a   Shu, Xiao Ou ^a   Cai, Hui ^a   Gao, Yu Tang ^b   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

Breast cancer; Estrogen metabolism; Single nucleotide polymorphism; Survival

Indexed keywords

TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; ENZYME ACTIVITY; ESTROGEN METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 34247240948     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32801a3bfe     Document Type: Article

References (37)

1. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21:427-433.
2. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19:1-27.
3. Dawling S, Hachey DL, Roodi N, Parl FF. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 2004; 17:1258-1264.
4. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003; 23:165-172.
5. Brueggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Joomprabutra S, Weitzel DH, et al. 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 2001; 78:145-156.
6. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000; 60:235-237.
7. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227:115-124.
8. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 1993; 3:213-230.
9. Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000; 87:295-300.
10. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65:5015-5019.
11. Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 2004; 64:836-839.
12. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, et al. Populationbased case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 2006; 16:237-243.
13. Boyapati SM, Shu XO, Gao YT, Cai Q, Jin F, Zheng W. Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. Cancer 2005; 103:2228-2235.
14. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:329-335.
15. Jin F, Devesa SS, Chow WH, Zheng W, Ji BT, Frauneni JF Jr, Gao YT. Cancer incidence trends in urban Shanghai, 1972-1994: an update. Int J Cancer 1999; 83:435-440.
16. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6:243-250.
17. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol- Omethyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001; 61:6716-6722.
18. Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 2002; 12:517-528.
19. Matsui A, Ikeda T, Enomoto K, Nakashima H, Omae K, Watanabe M, et al. Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett 2000; 150:23-31.
20. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002; 62:3052-3057.
21. Schwarz D, Kisselev P, Cascorbi I, Schunck WH, Roots I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001; 22:453-459.
22. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15:2961-2963.
23. Schwarz D, Kisselev P, Chernogolov A, Schunck WH, Roots I. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem Biophys Res Commun 2005; 336:779-783.
24. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997; 231:227-230.
25. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996; 56:3926-3933.
26. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2005; 14:1521-1527.
27. Chacko P, Joseph T, Mathew BS, Rajan B, Pillai MR. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res 2005; 581:153-163.
28. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991; 48:720-725.
29. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4:242-246.
30. Tabor HK, Risch NJ, Myers RM. Opinion: candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002; 3:391-397.
31. Voso MT, D'Alo' F, Gumiero D, Guidi F, Hohaus S, Leone G. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005; 90:982-984.
32. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449.
33. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60:3440-3444.
34. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20:1607-1613.
35. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000; 10:343-353.
36. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002; 61:586-594.
37. Smart J, Daly AK. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000; 10:11-24.